An observational study in Atrial Fibrillation, Cardiovascular Diseases and Thromboembolism, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-22.
Sponsored by Insel Gruppe AG, University Hospital Bern · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Atrial Fibrillation by Insel Gruppe AG, University Hospital Bern — 6 open to participants now, 8 under way, none of them phase 3. Atrial Fibrillation · Insel Gruppe AG, University Hospital Bern.
Among the 19 studies in Atrial Fibrillation by Insel Gruppe AG, University Hospital Bern, this one is one of 2 that started in 2015, is one of 9 observational ones, and was the 9th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →6 of the 19 studies in Atrial Fibrillation by Insel Gruppe AG, University Hospital Bern are open now, in 10 countries. Recruiting first, the newest first:
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Belgium, Germany, New Zealand and 3 more countries
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Belgium, France, Germany and 6 more countries
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18–85
Insel Gruppe AG, University Hospital Bern · Sites in Poland, Switzerland, United Kingdom
Ages 18+
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 300 across 1,405 observational studies indexed under Atrial Fibrillation.
Median enrollment 208 across the 10 interventional studies, 60 across the 9 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
Insel Gruppe AG, University Hospital Bern is the lead sponsor of 744 studies on the registry; 182 are open to participants now.
1 of the studies in Atrial Fibrillation by Insel Gruppe AG, University Hospital Bern that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07852221Insel Gruppe AG, University Hospital BernPatient Selection and Long-Term Outcomes of Pace & Ablate Strategy in Atrial Fibrillation | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Atrial Fibrillation by Insel Gruppe AG, University Hospital Bern, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims at comparing, in a large cohort of consecutive clinically indicated left atrial appendage closure, clinical and imaging outcomes between different subpopulations.
Percutaneous left atrial appendage closure (LAAC) has established itself in clinical practice as a safe and efficient therapeutic option for atrial fibrillation patients with a relative/absolute contraindication to oral anticoagulation. The purpose of this observational study is to prospectively collect procedural and follow-up data of all patients submitted to a clinically indicate LAAC in order to assess the impact of patient characteristics, procedural technique (imaging used to guide/plan procedure, device implanted, post-procedural drug regimens, etc.) on procedural safety and efficacy. The endpoints will be assessed by means of clinical follow-up at 1-3-5 years after LAAC and imaging exams (TEE at1-3 months, CCTA at 1-13months).
Patients with paroxysmal, persistent, or permanent non-valvular AF and CHA2DS2-VASc Score of ≥2 that are scheduled to undergo to an elective Left Atrial Appendage Closure
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Since August 2015, the echocardiography is routinely used by majority of operators to guide LAAC
Primary Safety Endpoint
Composite of Death, cerebrovascular events, cardiac tamponade, need for urgent surgery, need for cardiopulmonary resuscitation, device embolization, non vascular access-related major or life-threatening bleeding (according to the Bleeding academic research Criteria (BARC) type 3a, 3b, 3c, or 5) or acute kidney injury.
Time frame: 7 days
Primary Efficacy Endpoint - Incidence of cardiovascular death, ischemic stroke and systemic embolism
Protection from cardiovascular death, ischemic stroke and systemic embolism
Time frame: 1 to 5 Years
Secondary Efficacy Endpoint - Incidence of technical success
Technical success defined as adequate LAA ostium closure (without residual PDL\>5mm or patent lobes) in absence of device complications (according to the Munich Consensus Document)
Time frame: 7 days to 13 months
Feasibility Endpoint - Total procedure time (min)
Total procedure time (min)
Time frame: During the LAAC Procedure (≃ 60 minutes )
Feasibility Endpoint - dose of contrast medium (ml)
dose of contrast medium (ml)
Time frame: During the LAAC Procedure (≃ 60 minutes )
Feasibility Endpoint - dose of x-ray (cGy.cm2)
dose of x-ray (cGy.cm2)
Time frame: During the LAAC Procedure (≃ 60 minutes )
Feasibility Endpoint - number of device implantation attempt during the procedure (number)
number of device implantation attempt during the procedure (number)
Time frame: During the LAAC Procedure (≃ 60 minutes )
Feasibility Endpoint - number of device change during the procedure (number)
number of device change during the procedure (number)
Time frame: During the LAAC Procedure (≃ 60 minutes )
Net Clinical Benefit Endpoint
Composite of death, stroke, systemic embolism, pulmonary embolism, myocardial infarction, and major or life-threatening bleeding (according to the Bleeding academic research Criteria (BARC) type 3a, 3b, 3c, or 5) not procedure-related.
Time frame: 1 to 5 years
LAA patency
LAA patency and its subtypes as evaluated by TEE and/or CCTA
Time frame: 45 days to 13 months
Device related thrombus
Device related thrombus detected by TEE and /or CCTA on the atrial surface of device
Time frame: 45 days to 13months
Percentage of atrial surface of device covered
% (device sealing surrogate)
Time frame: 45 days - 3 months - 13months
Maximal Hypoattentuated Thickening on atrial surface of device
mm (device sealing surrogate)
Time frame: 45 days - 3 months - 13months
Percentage of device length coverage
% (device sealing surrogate)
Time frame: 45 days - 3 months - 13months
Started Aug 2015 (actual). Primary completion is estimated for Jun 2023, 93 months after the start.
Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's planned 93 months is above that.
Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Insel Gruppe AG, University Hospital Bern →